BORTEZOMIB FRESENIUS KABI 2.5 mg, powder for solution for injection bottle
Active ingredients: Bortezomib, ESTER BORONIQUE DE MANNITOL
Commercialized according to BDPMDispensing in France: Prescription only
Powder for solution for injectionbottleintraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BORTEZOMIB FRESENIUS KABI 2,5 mg, poudre pour solution injectable
- Pharmaceutical form
- poudre pour solution injectable
- Route of administration
- intraveineuse;sous-cutanée
- Presentation description
- 1 flacon(s) en verre
- Marketing authorisation holder
- FRESENIUS KABI DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Oct 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62600799CIP73022819CIP133400930228197Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ESTER BORONIQUE DE MANNITOLpoudre | — | SA |
| BORTÉZOMIBpoudre | 2,5 mg · un flacon | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.